Free Trial

Precigen (PGEN) Stock Price, News & Analysis

Precigen logo
$4.18 +0.54 (+14.84%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$4.14 -0.04 (-0.84%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Precigen Stock (NASDAQ:PGEN)

Key Stats

Today's Range
$3.62
$4.21
50-Day Range
$1.42
$4.18
52-Week Range
$0.65
$4.21
Volume
24.18 million shs
Average Volume
14.30 million shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25
Consensus Rating
Moderate Buy

Company Overview

Precigen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

PGEN MarketRank™: 

Precigen scored higher than 78% of companies evaluated by MarketBeat, and ranked 233rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Precigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Precigen has only been the subject of 4 research reports in the past 90 days.

  • Read more about Precigen's stock forecast and price target.
  • Earnings Growth

    Earnings for Precigen are expected to grow in the coming year, from ($0.32) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Precigen is -9.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Precigen is -9.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    19.71% of the float of Precigen has been sold short.
  • Short Interest Ratio / Days to Cover

    Precigen has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Precigen has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Precigen does not currently pay a dividend.

  • Dividend Growth

    Precigen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.71% of the float of Precigen has been sold short.
  • Short Interest Ratio / Days to Cover

    Precigen has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Precigen has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Precigen has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 37 news articles for Precigen this week, compared to 3 articles on an average week.
  • Search Interest

    35 people have searched for PGEN on MarketBeat in the last 30 days. This is an increase of 192% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Precigen to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Precigen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    47.10% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 33.51% of the stock of Precigen is held by institutions.

  • Read more about Precigen's insider trading history.
Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

PGEN Stock News Headlines

Precigen Inc. (PGEN) Stock Price Today - WSJ
Could This Be the End of Retirement Worries?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
Precigen Target of Unusually High Options Trading (NASDAQ:PGEN)
Precigen (PGEN) Gets a Buy from Cantor Fitzgerald
FY2026 EPS Estimates for Precigen Decreased by Analyst
Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright
See More Headlines

PGEN Stock Analysis - Frequently Asked Questions

Precigen's stock was trading at $1.12 at the beginning of 2025. Since then, PGEN stock has increased by 273.2% and is now trading at $4.18.

Precigen, Inc. (NASDAQ:PGEN) announced its quarterly earnings results on Tuesday, August, 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The biotechnology company earned $0.86 million during the quarter, compared to analyst estimates of $0.67 million. Precigen had a negative net margin of 2,868.66% and a negative trailing twelve-month return on equity of 842.83%.

Top institutional investors of Precigen include Patient Capital Management LLC (5.51%), Geode Capital Management LLC (1.27%), Bank of America Corp DE (0.28%) and JPMorgan Chase & Co. (0.26%). Insiders that own company stock include Helen Sabzevari, Randal J Kirk, Steven Frank, Jeffrey Thomas Perez, Donald P Lehr, Dean J Mitchell, Harry Jr Thomasian and Rutul R Shah.
View institutional ownership trends
.

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Nordic American Tankers (NAT), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Hess (HES) and Boeing (BA).

Company Calendar

Last Earnings
8/12/2025
Today
8/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PGEN
CIK
1356090
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

High Price Target
$8.50
Low Price Target
$8.00
Potential Upside/Downside
+97.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$126.24 million
Net Margins
-2,868.66%
Pretax Margin
-2,870.32%
Return on Equity
-842.83%
Return on Assets
-78.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.71
Quick Ratio
2.71

Sales & Book Value

Annual Sales
$3.92 million
Price / Sales
317.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-34.83

Miscellaneous

Outstanding Shares
297,970,000
Free Float
157,628,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
1.87

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:PGEN) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners